ArticleJournal of oral and maxillofacial pathology : JOMFP
Evaluation of the effectiveness of oral Pirfenidone in the treatment of oral submucous fibrosis: A non-randomised pilot clinical trial.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibrotic-Angiogenic Signaling Networks in Oral Submucous Fibrosis: Pathobiology and Therapeutic Targeting.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral submucous fibrosis (OSMF) is a potentially malignant disorder with a high rate of malignant transformation. Pirfenidone is an anti-fibrotic drug currently used in the treatment of idiopathic lung fibrosis (ILF). As both ILF and OSMF are mediated through transforming growth factor-beta, Pirfenidone could be beneficial in treating early stages of OSMF. Objectives: To evaluate the effectiveness of oral Pirfenidone in increasing the mouth opening, reducing fibrosis and burning sensation. Settings and Design: A single-arm prospective clinical trial conducted in the Department of Oral Medicine and Radiology, at a recognised dental college. Materials and Methods: Eleven subjects of either sex, of 21-55 years diagnosed with OSMF Stage 2 according to Chandramani More Results: 60% of the patients showed +1 unit of improvement with no serious adverse effect. Conclusions: The patient-related clinical outcomes were quite significant showing the effectiveness of Pirfenidone as a promising adjuvant therapy in the management of OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.